10-May-2024
TipRanks (Sun, 12-May 10:10 PM ET)
Cantor picks 14 undervalued biotech stocks worth a second look
Seeking Alpha News (Sun, 12-May 11:00 AM ET)
TipRanks (Fri, 10-May 8:20 AM ET)
Neutral Outlook on ACADIA Pharmaceuticals Amidst Revenue Miss and Revised Penetration Forecasts
TipRanks (Fri, 10-May 5:05 AM ET)
Buy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial Stability
TipRanks (Fri, 10-May 1:27 AM ET)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Business Wire (Thu, 9-May 4:58 PM ET)
TipRanks (Thu, 9-May 8:30 AM ET)
TipRanks (Thu, 9-May 6:57 AM ET)
RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)
TipRanks (Thu, 9-May 6:48 AM ET)
Maintaining Buy Rating on ACADIA Pharmaceuticals Amidst Daybue’s Long-Term Growth Prospects
TipRanks (Thu, 9-May 6:46 AM ET)
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Acadia Pharmaceuticals trades on the NASDAQ stock market under the symbol ACAD.
As of May 10, 2024, ACAD stock price climbed to $15.25 with 2,244,469 million shares trading.
ACAD has a beta of 1.44, meaning it tends to be more sensitive to market movements. ACAD has a correlation of 0.09 to the broad based SPY ETF.
ACAD has a market cap of $2.52 billion. This is considered a Mid Cap stock.
Last quarter Acadia Pharmaceuticals reported $206 million in Revenue and $.10 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.05.
In the last 3 years, ACAD stock traded as high as $33.99 and as low as $12.24.
The top ETF exchange traded funds that ACAD belongs to (by Net Assets): VTI, VB, XBI, IWM, VXF.
ACAD has underperformed the market in the last year with a price return of -29.6% while the SPY ETF gained +27.8%. ACAD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -42.1% and -8.7%, respectively, while the SPY returned +4.2% and +2.5%, respectively.
ACAD support price is $14.84 and resistance is $15.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACAD stock will trade within this expected range on the day.